UnicoCell Biomed Co., Ltd. (TWSE: 6794)
Health Care · Biotechnology · TW
NT$71.80
+0.84% today · -6.1% 1Y
UnicoCell Biomed Co., Ltd. (TWSE: 6794) operates in the Biotechnology industry within the Health Care sector. The company is valued at $143.49M and employs 27 people.
Over the last twelve months the share price has lost 6.1%, trading between 65.60 and 96.00.
Tweenvest scores UnicoCell Biomed Co., Ltd. across four factors: quality 33/100, value 50/100, growth 100/100. Its strongest factor is growth.
6794 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $143.49M
- Revenue (TTM)
- $705.99K
- P/E
- —
- EPS
- -1.65
- Dividend yield
- —
- Beta (5Y)
- -0.22
- 52-week high
- NT$96.00
- 52-week low
- NT$65.60
- Avg volume (3M)
- —
- Shares outstanding
- 63.64M
- Employees
- 27
- Next earnings
- —
About UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd., a Taiwanese enterprise, specializes in the research, development, and application of stem cell-based pharmaceuticals, advanced cell therapy techniques, and regenerative medical solutions. Their flagship product, ELIXCYTE, is presently undergoing Phase 2 clinical trials, targeting both osteoarthritis and chronic kidney disease. Beyond therapeutics, the company also offers UnicoVial, a specialized cryopreservation and drug containment system designed for cell therapy products, and provides a range of related testing services.
- ISIN
- TW0006794001
- Founded
- 2011
- Listed since
- May 13, 2024
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.07 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.98 | +0.26% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.96 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.00 | +0.26% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.94 | +0.78% |
| argenx SEENXTBR: ARGX | $63.06B | €872.80 | +1.00% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.62 | +1.97% |
Figures last refreshed Aug 18, 2026.